Abstract Number: 2515 • 2012 ACR/ARHP Annual Meeting
Low Density Lipoprotein Receptor Deficiency Results in Osteophyte Formation During Experimental Osteoarthritis Which Is Enhanced Under High Cholesterol Conditions
Background/Purpose: Synovial macrophages are involved in osteophyte formation during experimental collagenase-induced osteoarthritis (OA). Accumulated LDL can be oxidized in an inflammatory environment such as OA…Abstract Number: 2516 • 2012 ACR/ARHP Annual Meeting
Adenosine Receptors Stimulate Bone Regeneration by Targeting Osteoclasts
Background/Purpose: Various types of orthopedic procedures, including spinal fusion and repair of bone defects due to trauma, infection or metastatic disease, require formation of new…Abstract Number: 2517 • 2012 ACR/ARHP Annual Meeting
Inhibition of Notch Signaling Increases the Severity of Experimental Osteoarthritis
Background/Purpose: Notch signaling is triggered by binding of ligands such as Jagged-1 (Jag-1) to Notch receptors, which results in cleavage of Notch receptors by the…Abstract Number: 2518 • 2012 ACR/ARHP Annual Meeting
The Sphingosine-1-Phosphate Pathway Is a Key Regulator of Bone Substrate-Mediated Osteoclast Differentiation in Inflammatory Arthritis
Background/Purpose: Multiple lines of evidence have established that osteoclasts are required for physiologic bone resorption and pathological bone loss in inflammatory disorders. Isolation of differentiated…Abstract Number: 2519 • 2012 ACR/ARHP Annual Meeting
IL-1β and TNF-α Regulate the Global and Locus-Specific hydroxymethylation of Genomic DNA by Modulating the Expression and Activity of Tet-1 in Human OA Chondrocytes
Background/Purpose: 5-hydroxymethylcytosine (5-hmC), which is formed by the oxidation of 5-methylcytosine (5-mC), is a recently discovered epigenetic mark and is highest in brain and in…Abstract Number: 2520 • 2012 ACR/ARHP Annual Meeting
Suppressor of Cytokine Signaling 3 Is Reduced in Obese Patients with Osteoarthritis and Regulates Leptin Responses in Chondrocytes
Background/Purpose: Leptin is an adipokine whose concentrations in circulation are proportional to body fat stores and body mass index (BMI). Initially leptin was discovered to…Abstract Number: 2521 • 2012 ACR/ARHP Annual Meeting
Immunoglobulin G Fc Receptor Activity in Vivo Is Under Complement Control
Background/Purpose: Immunoglobulin G receptors (FcγR) are critical in the development of autoimmunity and pathogenesis of immune complex (IC) diseases. Although ICs activate complement, contributing to…Abstract Number: 2522 • 2012 ACR/ARHP Annual Meeting
M-Ficolin, an Activator of the Complement System, Is the Strongest Predictor of Both DAS28 Remission and Low Disease Activity in a Cohort of 180 Early DMARD Naïve Rheumatoid Arthritis Patients Followed in the Opera-Study
Background/Purpose: M-ficolin is a soluble pattern recognition molecule that activates the complement system. We recently reported a factor 300 difference in the synovial fluid M-ficolin…Abstract Number: 2523 • 2012 ACR/ARHP Annual Meeting
Periodontal Pathogens Directly Promote Autoimmune Experimental Arthritis by Inducing a Toll-Like Receptor 2 and Interleukin-1 Driven Th17 Response
Background/Purpose: The periodontal pathogen Porphyromonas gingivalishas been associated with the pathogenesis of rheumatoid arthritis (RA) because of its ability to citrullinate mammalian proteins and to…Abstract Number: 2524 • 2012 ACR/ARHP Annual Meeting
Snapin Is Critical for the Maturation of Autophagosome and Phagosome in Macrophages
Background/Purpose: We found that Snapin, a SNARE complex protein required for synaptic vesicle docking and fusion, was significantly increased in rheumatoid arthritis (RA) synovial tissue…Abstract Number: 2525 • 2012 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase Inhibition Suppresses Inflammatory Cytokine Production and Affects Gene Expression in Human Macrophages and RA Synovial Tissue Explants
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and progressive autoinflammatory disorder characterized by the infiltration of inflammatory cells, including B-cells, T-cells and macrophages, in the…Abstract Number: 2486 • 2012 ACR/ARHP Annual Meeting
Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This Phase 3, 24-mo study (ORAL…Abstract Number: 2487 • 2012 ACR/ARHP Annual Meeting
24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 24 week blinded…Abstract Number: 2488 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (formerly, LY3009104/ INCB028050 ) is a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT pathway. Primary results of this phase 2b…Abstract Number: 2489 • 2012 ACR/ARHP Annual Meeting
Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG0634
Background/Purpose: Janus kinases (JAKs) are critical components in signaling pathways for a number of cytokines and growth factors, including those involved in the disease process…
ACR Meeting Abstracts